Cross Country Healthcare (CCRN) just posted its FY 2025 numbers with Q4 revenue of US$236.8 million and a basic EPS loss of US$2.56, while trailing twelve month revenue came in at US$1.1 billion alongside a TTM basic EPS loss of US$2.93. Over recent quarters the company has seen revenue move from US$315.1 million in Q3 2024 to US$236.8 million in Q4 2025, with quarterly basic EPS shifting from a small profit of US$0.08 in Q3 2024 to a loss of US$2.56 in the most recent period. This points to compressed margins and a results season that keeps the focus squarely on how quickly profitability can be rebuilt.

See our full analysis for Cross Country Healthcare.

With the latest figures on the table, the next step is to set these earnings against the widely followed narratives to see which storylines still hold up and which ones the numbers start to challenge.

Losses widen to US$94.9 million over the year

• On a trailing twelve month basis, Cross Country Healthcare reported a net loss of US$94.9 million on US$1.1b in revenue, compared with a quarterly loss of US$82.9 million on US$236.8 million of revenue in Q4 2025 alone.
• Bears argue that a five year pattern of losses growing about 34% a year and recent weak margins could keep earnings under pressure, and the latest figures align with that concern as TTM EPS sits at a loss of US$2.93 while analysts still only expect margins to move to roughly 1% to 1.3% over the next three years.
  • The bearish narrative highlights reliance on tighter bill pay spreads and competitive pricing in travel staffing, which fits with the TTM loss of US$94.9 million despite more than US$1.0b in revenue.
  • At the same time, bearish analysts still model revenue around US$1.1b and earnings of US$14.0 million by 2029, so the current loss run rate sets a high bar for the margin improvement they outline.

Bears who see the recent US$94.9 million yearly loss as a warning flag can stress test that view against a fuller downside case in the 🐻 Cross Country Healthcare Bear Case.

Forecast 102.9% earnings growth vs modest 1.6% revenue

• Analysts in the supplied data expect earnings to grow at 102.9% per year with revenue at 1.6% per year, from a base of US$1.1b of trailing revenue and a TTM EPS loss of US$2.93.
• Bullish investors point to this sharp swing in earnings as well as mix shifts toward home based, education and physician staffing to argue that profit can recover, and the current numbers both support and stretch that view.
  • The bullish case assumes margins lift from roughly a 9% loss today to a 1.1% profit margin and earnings of US$12.2 million by around 2029, which would be a marked change from the current TTM net loss of US$94.9 million.
  • With revenue forecasts broadly flat around US$1.1b, that turnaround depends heavily on cost efficiency and higher margin segments rather than top line expansion, which means the TTM revenue base is in line with, not ahead of, the bullish narrative.

If you want to see how those aggressive profit forecasts stack up against the latest numbers, the bullish narrative lays the case out in detail in the 🐂 Cross Country Healthcare Bull Case.

P/S of 0.4x vs DCF fair value of US$46.81

• At a share price of US$13.09 and TTM revenue of about US$1.1b, Cross Country Healthcare trades on a P/S of 0.4x compared with peer and US Healthcare industry averages of 2.3x and 1.2x, while a DCF fair value of US$46.81 has also been provided in the data.
• Consensus style commentary points out that this wide gap in P/S multiples and the higher DCF fair value only becomes meaningful if the expected improvement to roughly 1% profit margins and earnings of about US$10.8 million by 2029 actually shows up.
  • The single allowed analyst target in this data set is US$11.38, which sits slightly below the current US$13.09 share price, so the valuation picture looks quite different depending on whether investors focus on that target or the DCF fair value of US$46.81.
  • Given trailing results still show a TTM EPS loss of US$2.93 and a TTM net loss of US$94.9 million, the low P/S and higher DCF fair value rest on future margin expansion rather than any sign of profitability in the latest year.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cross Country Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given that the latest results leave room for both concern and optimism, it makes sense to check the numbers yourself and decide where you stand. To see how the positives and negatives balance out in one place, take a look at the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Cross Country Healthcare is working through a US$94.9 million trailing loss, compressed margins and profit forecasts that depend heavily on margin improvement rather than revenue growth.

If that mix of losses and execution risk feels uncomfortable, consider balancing it by looking at companies with steadier fundamentals through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.